Tissue inhibitor of matrix metalloproteinase-1 in norepinephrine-induced remodeling of the mouse heart

Cellular Physiology and Biochemistry

Volumn 20, Issue 6, 2007, Pages 825-836

  Meier, Henning ^a   Bullinger, Jörg ^a   Deten, Alexander ^a   Marx, Grit ^a   Rabald, Steffen ^a   Zimmer, Heinz Gerd ^a   Briest, Wilfried ^a,b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Adrenergic agonists; Extracellular matrix; Hypertrophy; Matrix metalloproteinases; Ventricular remodeling

Indexed keywords

ANTIBODY; ATRIAL NATRIURETIC FACTOR; COLLAGEN TYPE 1; COLLAGEN TYPE 3; MESSENGER RNA; NORADRENALIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; HEART HYPERTROPHY; HEART MUSCLE CONTRACTILITY; HEART MUSCLE RELAXATION; HEART VENTRICLE FAILURE; HEART VENTRICLE REMODELING; LUNG CONGESTION; MALE; MOUSE; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; SYSTOLIC BLOOD PRESSURE;

MUS;

ANIMALS; BODY WEIGHT; ENZYME INHIBITORS; EXTRACELLULAR MATRIX; EXTRACELLULAR MATRIX PROTEINS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEART; HEART FUNCTION TESTS; HEART VENTRICLES; HYPERTROPHY; LUNG; MALE; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; NOREPINEPHRINE; ORGAN SIZE; RNA, MESSENGER; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; VENTRICULAR REMODELING;

EID: 35848957721     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000110442     Document Type: Article

References (26)

1. Kerkela R, Force T: Recent insights into cardiac hypertrophy and left ventricular remodeling. Curr Heart Fail Rep 2006;3:14-8.
2. Miner EC, Miller WL. A look between the cardiomyocytes: the extracellular matrix in heart failure. Mayo Clin Proc 2006;81:71-6.
3. Deschamps AM, Spinale FG: Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation. Cardiovasc Res 2006;69:666-76.
4. Briest W, Hölzl A, Raßler B, Deten A, Leicht M, Baba HA, Zimmer H-G: Cardiac remodeling after long term norepinephrine treatment in rats. Cardiovasc Res 2001;52:265-73.
5. Nishikimi T, Maeda N, Matsuoka H: The role of natriuretic peptides in cardioprotection. Cardiovasc Res 2006;69:318-28.
6. Barth W, Deten A, Bauer M, Reinohs M, Leicht M, Zimmer H-G: Differential remodeling of the left and right heart after norepinephrine treatment in rats: studies on cytokines and collagen. J Mol Cell Cardiol 2000;32:273-84.
7. Briest W, Hölzl A, Raßler B, Deten A, Baba HA, Zimmer H-G: Significance of matrix metalloproteinases in norepinephrine-induced remodelling of rat hearts. Cardiovasc Res 2003;57:379-87.
8. Briest W, Homagk L, Raßler B, Ziegelhöffer-Mihalovicová B, Meier H, Tannapfel A, Leiblein S, Saalbach A, Deten A, Zimmer H-G: Norepinephrine-induced changes in the rat cardiac TGF-beta isoform expression pattern. Hypertension 2004;44:410-8.
9. Deten A, Volz HC, Clamors S, Leiblein S, Briest W, Marx G, Zimmer H-G: Hematopoietic stem cells do not repair the infarcted mouse heart. Cardiovasc Res 2005;65:52-63.
10. Briest W, Homagk L, Baba HA, Deten A, Raßler B, Tannapfel A, Wagner KF, Wenger RH, Zimmer H-G: Cardiac remodeling in erythropoietin-transgenic mice. Cell Physiol Biochem 2004;14:277-84.
11. Lanchou J, Corbel M, Tanguy M, Germain N, Boichot E, Theret N, Clement B, Lagente V, Malledant Y: Imbalance between matrix metalloproteinases (MMP-9 and MMP-2) and tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in acute respiratory distress syndrome patients. Crit Care Med 2003;31:536-42.
12. Zierhut W, Zimmer H-G: Significance of myocardial alpha- and beta-adrenoceptors in catecholamine-induced cardiac hypertrophy. Circ Res 1989;65:1417-25.
13. Marino TA, Cassidy M, Marino DR, Carson NL, Houser S: Norepinephrine-induced cardiac hypertrophy of the cat heart. Anat Rec 1991;229:505-10.
14. Laks MM, Morady F, Swan HJ: Myocardial hypertrophy produced by chronic infusion of subhypertensive doses of norepinephrine in the dog. Chest 1973;64:75-8.
15. Tsoporis JN, Marks A, Kahn HJ, Butany JW, Liu PP, O'Hanlon D, Parker TG: Inhibition of norepinephrine-induced cardiac hypertrophy in S100beta transgenic mice. J Clin Invest 1998;102:1609-16.
16. Vecchione C, Fratta L, Rizzoni D, Notte A, Poulet R, Porteri E, Frati G, Guelfi D, Trimarco V, Mulvany MJ, Agabiti-Rosei E, Trimarco B, Cotecchia S, Lembo G: Cardiovascular influences of alpha1b-adrenergic receptor defect in mice. Circulation 2002;105:1700-7.
17. Nakagawa O, Ogawa Y, Itoh H, Suga S, Komatsu Y, Kishimoto I, Nishino K, Yoshimasa T, Nakao K: Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload. J Clin Invest 1995;96:1280-7.
18. Irlbeck M, Mühling O, Iwai T, Zimmer H-G: Different response of the rat left and right heart to norepinephrine. Cardiovasc Res 1996;31:157-62.
19. Deten A, Shibata J, Scholz D, Briest W, Wagner KF, Wenger RH, Zimmer HG: Norepinephrine-induced acute heart failure in transgenic mice overexpressing erythropoietin. Cardiovasc Res 2004;61:105-14.
20. Teboul JL, Douguet D, Mercat A, Depret J, Richard C, Zelter M: Effects of catecholamines on the pulmonary venous bed in sheep. Crit Care Med 1998;26:1569-75.
21. Yang CM, Kandaswamy V, Young D, Sen S: Changes in collagen phenotypes during progression and regression of cardiac hypertrophy. Cardiovasc Res 1997;36:236-45.
22. Baker AH, Edwards DR, Murphy G: Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002;115:3719-27.
23. Gasson JC, Golde DW, Kaufman SE, Westbrook CA, Hewick RM, Kaufman RJ, Wong GG, Temple PA, Leary AC, Brown EL: Molecular characterization and expression of the gene encoding human erythroid-potentiating activity. Nature 1985;315:768-71.
24. Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K: Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett 1992;298:29-32.
25. Lovelock JD, Baker AH, Gao F, Dong JF, Bergeron AL, McPheat W, Sivasubramanian N, Mann DL: Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblasts. Am J Physiol Heart Circ Physiol 2005;288:H461-8.
26. Bubikat A, De Windt LJ, Zetsche B, Fabritz L, Sickler H, Eckardt D, Godecke A, Baba HA, Kuhn M: Local atrial natriuretic peptide signaling prevents hypertensive cardiac hypertrophy in endothelial nitric-oxide synthase-deficient mice. Journal of Biological Chemistry 2005;280:21594-9.